The effect of equine hyperimmune sera on TNF alpha activity in a L929 cell bioassay by Kotiw, M. et al.
Proc. Aust. Equine Sc. Symp., Vol 1, 2006 
22 
                 	   
        	       	   	            
  	     
           

 
M. Kotiw
A
, C. Raghaven
A
, M. Johnson
A
, I.A. Shiels
B
 and R.P. Wilson
C
 
A Centre for Systems Biology, University of Southern Queensland, Toowoomba Qld 4350 
B 
School of Biomedical Sciences, University of Queensland, St Lucia, Qld 4072 
C 
Plasvacc Pty Ltd, 6066 Cunningham Highway, Kalbar, Qld 4309 
Adult equine endotoxaemia (AEE) remains a major cause of equine morbidity and mortality. 
The syndrome is common in horses presenting with acute abdominal disorders such as 
intestinal strangulation and severe colitis
1
. Death may result from an endotoxin (also known 
as lipopolysaccharide or LPS) induced, cytokine mediated, hyperinflammatory cascade that 
can lead to hypovolemic shock, coagulopathy and catastrophic multiple organ failure
2
. 
Endotoxin is a lipid A moiety located in the outer membrane of Gram negative bacteria such 
as intestinal Escherichia coli. The toxin may gain access to the systemic circulation through 
loss of gut mucosal integrity induced by events such as severe colitis, either by translocation 
of live bacteria or endotoxin leakage from the gut lumen
3
. Endotoxin is then rapidly bound to 
an LPS binding protein (LPB) in serum which potentiates its presentation to antigen 
presenting cells such as macrophages. Activated macrophages secrete inflammatory 
cytokines- predominantly TNFα and IL1β which initiate the uncontrolled cascade leading to a 
potential for the catastrophic pathology
4
.  
Because of haemodynamic instability and associated hypovolemia, fluid replacement therapy 
is generally applied to restore effective circulating volume
5
. The use of fresh frozen plasma 
has been recommended in cases of coagulopathies as it has been recognized to assist 
restoration of haemodynamic stability
6
.  
In this pilot study we examined the effect of sera from a proprietary hyperimmune plasma 
product (Equiplas) on the activity of TNFα in an in vitro L929 cell bioassay
7
. In brief, we 
report observations from 2 accessions of sera. Accession 1 describes the antiTNFα activity of 
3 hyperimmune sera and an untreated serum sample that were provided blind to the study. 
Accession 2 reports a comparison of antiTNFα activity found in 3 paired hyperimmune sera 
collected following a multiple endotoxin vaccination regimen.  
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AntiTNFα activity of Equine sera
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Figure 2.  
Effect of Donor A 1st serum sample on TNFα activity 
 
Figure 3.  
Effect of Donor A 2nd serum sample on TNFα activity  
(2nd sample was taken after further endotoxin vaccination) 
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We report here observations which we acknowledge require further work for statistical 
validation. 
       
 suggests that there is intrinsic antiTNFα activity in all equine sera 
(Accession 1), including the untreated equine serum. It also appears that the proprietary 
endotoxin vaccination regimen employed in the preparation of hyperimmune plasma 
(Equiplas) enhances the antiTNFα activity of serum, as all 3 hyperimmune samples appear to 
exhibit greater activity than the untreated serum (although one specimen of hyperimmune 
serum appears to be only marginally enhanced). 
        
 &  are representative of results 
for a donor subjected to a 2
nd
 regimen of endotoxin vaccination. The results suggest that in 
some cases there may be further enrichment of antiTNFα bioactivity 
      
 	 
  However, 
only 2 of the 3 donors subjected to further vaccination (Accession 2) demonstrated such 
enhancement. If these results are indicative of what occurs, then it may not be too surprising 
to find that there is an intrinsic biological limit to the titre achievable for an active factor. 
Whilst it is known that TNFα is rapidly degraded at the cellular level by neutrophil derived 
proteases, there is increasing evidence that the cytokine is also modulated in the systemic 
circulation by solubilized TNFα receptors (sTNFR)
8
. The sTNFRs appear to be solubilised 
from parent cell membranes by proteases in the presence of excess TNFα and may be a host 
means for moderating the cytokine’s systemic influences
8,9
. Whilst our observations are 
preliminary and require confirmation, it does seem plausible that the endotoxin vaccination 
regimen used in the preparation of the hyperimmune plasma may similarly stimulate the 
systemic release of sTNFRs and so account, at least in part, for the apparent antiTNFα 
activity. Clearly, further work needs to be undertaken to confirm our observations and to 
determine the nature of the antiTNFα activity.   
This study was funded by a collaborative initiative between Plasvacc Pty Ltd and the 
University of Southern Queensland. 
ROY, M.F. (2004) Vet Clin North Am Equine Pract. 20(1):41-61 
SOUTHWOOD, L.L. (2004) Vet Clin North Am Equine Pract. 20(1):167-197 
TOMLINSON, J.E. & BLIKSLAGER, A.T. (2004) AJVR 65:1377-1383 
TINKER, M.K et al., (1994) Equine Vet J 29:448-453 
LUCUS, C.E. et al., (1995) Am J Surgery 171:399-404 
HELSTERN, P. & HAUBELT, H. (2002) Thrombosis Research 107:S19-S22 
WADHWA, M. et al., (1995) In Cytokines: a practical approach (Ed FR Balkwill) IRL Press, Oxford pp 357-
391 
ADERKA, D et al., (1998) J Clin Invest. 101:650-659 
ALEXANDER, W & HILTON, D (2004) Ann Rev Immunol 22:503-529 
